ABSTRACT
Introduction The assessment of empirical epidemiological data is needed to assess the transmissibility of SARS-CoV-2 in aircraft settings. This review summarises reported contact- tracing data and evaluates the secondary attack rates (SAR) and factors associated with SARS- CoV-2 transmission in aircraft, to provide insight for future decision making in the context of future respiratory pandemics.
Methods This scoping literature review assessed studies published between December 2020 to November 2023 in Ovid Medline, Embase and Cochrane Library databases. The inclusion criteria were based on the PCC framework (P-Population, C-Concept, C-Context). The study population was restricted to passengers and crew (population) to assess transmission (concept) in an aircraft setting (context).
Results Thirty-one studies which assess SARS-CoV-2 transmission in 521 domestic and international flights were included in this systematic review. The SAR reported in the studies with an identified index case ranged from 0% to 16%. Significant variation in the reporting across studies was noted. Overall, the studies reported that using face masks or respirators by passengers and crew members during flight seemed to be a possible strategy for mitigating SARS-CoV-2 transmission while sitting within close proximity to index cases (≤2 seats in every direction) was associated with a higher SAR.
Conclusions Our results are consistent with sporadic clusters happening onboard aircraft. Close proximity to COVID-19 cases within the aircraft was associated with a higher SAR. Our findings further underscore the need for a systematic approach to examining and reporting SARS-CoV-2 transmission onboard aircraft. This evidence may assist policymakers and transportation authorities in the development of emergency preparedness measures and travel guidance during the post-pandemic COVID-19 era.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This report was produced under a service contract 17-ECD.12552, within Framework contract ECDC/2019/001 Lot 1B, with the European Centre for Disease Prevention and Control (ECDC), acting under the mandate from the European Commission.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
2
Blogs/Media
Author Videos